lung
transplant
chronic
lung
allograft
dysfunct
bronchiol
obliteran
bronchiol
obliteran
syndrom
neutrophil
revers
allograftairway
dysfunct
macrolid
christian
knoop
md
phd
marc
estenn
md
phd
bronchiol
obliteran
bo
context
lung
transplant
first
describ
stanford
univers
patient
develop
progress
airflow
obstruct
heartlung
transplant
lung
biopsi
reveal
intralumin
polyp
fibromyxoid
granul
tissu
tend
obliter
lumen
termin
bronchiol
dens
submucos
eosinophil
fibrou
scar
fig
sinc
earli
report
bo
recogn
major
complic
lead
caus
death
lung
transplant
small
airway
lesion
patchi
distribut
hardli
demonstr
transbronchi
lung
biopsi
tbb
low
sensit
specif
result
order
establish
diagnosi
bo
without
need
open
lung
biopsi
intern
societi
heart
lung
transplant
ishlt
propos
clinic
definit
base
pulmonari
function
criteria
term
bronchiol
obliteran
syndrom
bo
coin
identifi
patient
progress
irrevers
declin
forc
expiratori
volum
one
second
fev
initi
classif
bo
divid
stage
base
degre
loss
fev
compar
best
postop
valu
updat
classif
propos
potenti
bo
bo
stagedefin
declin
fev
midexpiratori
flow
rate
fef
ad
detect
earli
potenti
import
chang
pulmonari
function
tabl
sever
condit
need
satisfi
patient
classifi
stage
system
function
loss
present
least
week
exclud
acut
revers
process
loss
includ
decreas
fev
fev
vital
capac
ratio
ie
patient
loss
fev
context
restrict
ventilatori
defect
consid
bo
confound
condit
may
produc
decreas
fev
eg
infect
acut
reject
anastomot
complic
diseas
recurr
progress
nativ
lung
hyperinfl
patient
singlelung
transplant
slt
emphysema
need
exclud
transplant
center
worldwid
adopt
stage
system
descriptor
chronic
lung
allograft
dysfunct
prove
use
provid
common
languag
classifi
patient
compar
result
program
sever
limit
howev
becom
appar
recent
year
first
mani
patient
confound
condit
stage
bo
second
experi
lung
transplant
accru
increas
number
patient
present
form
chronic
allograft
dysfunct
compris
characterist
featur
bo
sever
type
chronic
allograft
dysfunct
differ
bo
identifi
past
year
includ
revers
phenotyp
character
airway
neutrophilia
function
improv
azithromycin
azm
phenotyp
character
restrict
ventilatori
impair
associ
upper
lobe
fibrosi
persist
parenchym
pleural
abnorm
exud
follicular
bronchiol
larg
airway
stenosismalacia
review
deal
primarili
classic
bo
extens
studi
recent
describ
present
chronic
allograft
dysfunct
also
address
registri
report
ishlt
publish
freedom
bo
cohort
patient
follow
april
june
year
year
year
year
surgeri
percentag
repres
clear
decreas
preval
complic
compar
earlier
seri
yet
bo
remain
far
signific
longterm
complic
lead
caus
late
death
lung
transplant
account
death
third
postop
year
bo
may
affect
lung
transplant
recipi
irrespect
donor
recipi
characterist
type
transplant
pretranspl
diseas
clinic
present
bo
heterogen
type
present
time
transplant
onset
rate
progress
variabl
patient
fig
bo
may
present
acut
ill
imit
respiratori
infect
patient
start
asymptomat
process
produc
insidi
declin
lung
function
approxim
patient
bo
develop
within
year
transplant
earlyonset
bo
vast
major
patient
develop
complic
later
point
time
patient
present
substanti
loss
lung
function
alreadi
bo
stage
highgrad
onset
present
wherea
other
show
slow
declin
time
studi
jackson
colleagu
patient
develop
bo
show
sudden
drop
fev
wherea
present
smooth
linear
declin
time
bo
onset
longer
latter
group
acut
reject
first
month
significantli
associ
acut
onset
bo
auscult
lung
often
normal
squeak
coars
crackl
may
heard
highresolut
ct
may
reveal
air
trap
fig
bronchiectasi
without
signific
parenchym
infiltr
diseas
progress
perman
airway
colon
pathogen
pseudomona
aeruginosa
aspergillu
fumigatu
frequent
develop
surviv
year
diagnosi
rang
surviv
year
transplant
lower
patient
compar
patient
without
bo
also
evid
number
respiratori
infect
aggress
treat
impact
bo
progress
addit
repres
major
obstacl
longterm
surviv
bo
caus
signific
morbid
loss
healthrel
qualiti
life
bo
use
surrog
marker
bo
equal
bo
therefor
expect
function
marker
drop
fev
like
low
specif
diagnosi
bo
exclusionari
criteria
ad
definit
bo
lack
specif
difficult
assess
gold
standard
rare
avail
yet
studi
lung
explant
time
retransplant
bo
patholog
examin
alway
show
least
degre
bo
wide
rang
patholog
process
potenti
clinic
signific
also
evid
half
specimen
contrast
classic
bo
character
progress
irrevers
airflow
obstruct
parenchym
pleural
abnorm
recent
describ
new
phenotyp
chronic
allograft
dysfunct
may
includ
one
follow
featur
partial
revers
airway
obstruct
restrict
ventilatori
impair
parenchymalpleur
abnorm
larg
airway
stenosismalacia
well
known
macrolid
antibiot
effect
treat
airway
diseas
like
bo
associ
neutrophil
inflamm
eg
panbronchiol
cystic
fibrosi
gerhardt
colleagu
perform
open
trial
azm
lung
transplant
recipi
studi
azm
mg
time
week
ad
current
immunosuppress
treatment
patient
bo
patient
respond
mean
improv
fev
week
one
patient
even
complet
restor
fev
peak
posttranspl
valu
landmark
studi
follow
least
studi
confirm
result
publish
gerhardt
colleagu
one
studi
benden
colleagu
also
report
posit
effect
clarithromycin
fev
take
public
togeth
approxim
patient
differ
bo
stage
respond
macrolid
treatment
mean
increas
fev
approxim
furthermor
higher
bronchoalveolar
lavag
bal
fluid
neutrophilia
associ
greater
likelihood
function
respons
base
observ
verleden
colleagu
suggest
bo
might
dichotom
azmrespons
phenotyp
character
airway
neutrophilia
function
improv
azm
socal
neutrophil
revers
allograftairway
dysfunct
nrad
azmunrespons
phenotyp
correspond
classic
fibroprolif
form
bo
two
phenotyp
might
differ
pathophysiolog
clinic
present
prognosi
exampl
nrad
might
start
earlier
transplant
progress
slower
fibroprolif
bo
crackl
increas
sputum
product
bronchiectasi
mucu
plug
might
promin
former
latter
joint
retrospect
studi
toronto
gener
hospit
duke
univers
hospit
identifi
lung
transplant
recipi
develop
upper
lobe
fibrosi
radiograph
chang
start
initi
nonspecif
interstiti
mark
upper
lobe
slowli
progress
honeycomb
traction
bronchiectasi
volum
loss
fig
patient
restrict
ventilatori
defect
eventu
develop
concomit
airflow
obstruct
open
lung
biopsi
specimen
reveal
dens
interstiti
fibrosi
occasion
featur
bo
acut
fibrin
organ
pneumonia
bronchiol
obliteran
organ
pneumonia
aspir
rate
progress
clinic
symptom
rang
slow
rapid
overal
condit
poor
prognosi
preval
caus
form
chronic
allograft
dysfunct
still
unclear
recent
woodrow
colleagu
report
lung
transplant
recipi
declin
lung
function
associ
persist
parenchym
alveolar
nodular
groundglass
interstiti
abnorm
chest
ctnot
specif
involv
upper
lobe
fig
precis
caus
found
parenchym
infiltr
patient
show
function
deterior
time
parallel
cours
patient
classic
bo
similar
proport
patient
approxim
restrict
ventilatori
defect
group
group
without
parenchym
infiltr
studi
woodrow
colleagu
radiograph
abnorm
pleural
anoth
studi
show
year
transplant
patient
pleural
abnorm
frequent
pleural
thicken
chest
ct
abnorm
may
obvious
restrict
lung
volum
relationship
process
chronic
reject
longterm
impact
remain
clarifi
mcmanu
colleagu
report
transplant
recipi
present
exud
bronchiol
appear
highresolut
ct
treeinbud
pattern
centrilobular
nodul
branch
line
condit
associ
earli
infect
posttranspl
histori
aspergillu
infect
neutrophil
count
bronchial
wash
increas
patient
improv
clinic
radiolog
azm
yet
exud
bronchiol
increas
markedli
likelihood
develop
bo
recent
vo
colleagu
describ
patient
develop
follicular
bronchiol
character
abund
peribronchiolar
lymphoid
follicul
condit
also
associ
develop
bo
larg
airway
stenosismalacia
recent
articl
akindip
colleagu
report
patient
retranspl
sever
recurr
airway
narrow
patient
allograft
lung
patholog
reveal
evid
bo
observ
suggest
possibl
link
airway
ischemiahypoxia
earlier
day
lung
transplant
bosbo
believ
equival
chronic
allograft
reject
ie
process
caus
alloimmun
reaction
lung
uniqu
expos
environ
howev
thu
recurr
nonalloimmun
insult
infect
inhal
toxic
fume
gastroesophag
reflux
furthermor
recent
studi
suggest
possibl
role
autoantibodi
develop
specif
epitheli
protein
airway
hypoxia
pathogenesi
bosbo
current
view
insult
act
alon
combin
upregul
dendritr
cell
airway
epithelium
lead
epitheli
damag
inflamm
product
chemokin
cytokin
airway
epithelium
smooth
muscl
cell
macrophag
neutrophil
activ
neutrophil
increas
epitheli
damag
via
product
reactiv
oxygen
speci
metalloproteinas
initi
inflammatori
phase
fibroprolif
phase
occur
driven
growth
factor
lead
prolifer
smooth
muscl
cell
myofibroblast
process
eventu
result
aberr
collagen
deposit
excess
fibroprolifer
small
airway
obliter
bo
would
thu
repres
final
common
pathway
lesion
secondari
multipl
repetit
insult
airway
epithelium
alloimmun
risk
factor
ninetyf
percent
patient
receiv
graft
hla
mismatch
use
collabor
transplant
studi
databas
graft
outcom
accord
hla
mismatch
examin
lung
transplant
perform
graft
surviv
rate
show
stepwis
decreas
combin
number
mismatch
increas
high
number
hla
mismatch
unfavor
impact
surviv
averag
high
number
mismatch
studi
examin
effect
hla
mismatch
incid
acut
reject
prove
difficult
result
inconsist
howev
identifi
neg
impact
hla
mismatch
multivari
logist
regress
analys
data
adult
lung
transplant
recipi
retriev
unit
network
organ
sharingishlt
registri
demonstr
associ
mismatch
hlaa
locu
hlab
hladr
loci
acut
reject
episod
requir
hospit
admiss
sever
studi
confirm
develop
antihla
class
class
ii
antibodi
surgeri
associ
risk
acut
reject
bo
bind
antibodi
airway
epitheli
cell
may
induc
epitheli
injuri
prolifer
acut
vascular
reject
histolog
grade
greater
equal
identifi
mani
studi
statist
risk
factor
bo
patient
cf
transplant
year
develop
acut
rapidli
progress
complet
therapyresist
drop
lung
function
ct
scan
lung
repeatedli
show
peripher
infiltr
upper
also
lower
b
lung
zone
bal
show
promin
neutrophilia
alsoeven
lesser
extenteosinophilia
infecti
agent
could
incrimin
particular
diagnost
criteria
invas
pulmonari
aspergillosi
eventu
could
undergo
redodoubl
lung
transplant
explant
lung
show
zone
nonspecif
interstiti
fibrosi
pneumocyt
hyperplasia
fibroblast
prolifer
area
parenchym
abnorm
advanc
bo
lesion
lung
region
yousem
report
untreat
acut
vascular
reject
grade
lead
develop
bo
patient
sever
studi
shown
risk
bo
increas
acut
vascular
reject
histolog
sever
persist
recur
treatment
studi
review
knoop
estenn
impact
minim
acut
reject
grade
develop
bo
howev
long
neglect
recent
studi
hopkin
colleagu
less
grade
reject
associ
clinic
symptom
asymptomat
patient
progress
highergrad
acut
reject
lymphocyt
bronchiol
lb
within
month
report
also
patient
multipl
episod
first
month
posttranspl
significantli
higher
risk
develop
bo
occur
earlier
patient
less
grade
episod
khalifa
colleagu
retrospect
examin
data
lung
transplant
patient
follow
period
confirm
grade
reject
distinct
risk
factor
bo
hachem
colleagu
group
determin
even
singl
episod
reject
without
recurr
subsequ
progress
higher
reject
grade
signific
risk
factor
develop
bo
treatment
grade
reject
divers
approach
order
augment
net
immunosuppress
decreas
risk
subsequ
progress
bo
stage
lb
absenc
acut
vascular
reject
may
also
predat
bo
glanvil
colleagu
retrospect
assess
data
tbb
specimen
obtain
patient
period
year
show
cumul
incid
bo
significantli
associ
sever
lb
anoth
retrospect
analysi
tbb
specimen
obtain
nearli
consecut
patient
follow
first
postop
year
univers
copenhagen
show
cumul
incid
lb
month
month
month
month
respect
approxim
patient
second
episod
grade
higher
within
month
year
transplant
respect
studi
lb
first
year
independ
associ
frequenc
andor
sever
acut
reject
lb
grade
higher
associ
increas
risk
bo
concept
acut
chronic
antibodymedi
reject
still
controversi
lung
transplant
well
document
report
type
reject
exist
howev
data
possibl
contribut
chronic
allograft
dysfunct
begin
appear
observ
patient
develop
hla
antibodi
fare
less
well
novel
data
selfantibodi
direct
epitheli
antigen
patient
bosbo
discuss
later
lend
credibl
hypothesi
recent
develop
autoimmun
process
direct
epithelialspecif
protein
incrimin
develop
bosbo
one
studi
collagen
type
vreactiv
cell
associ
nearli
increas
risk
bo
clinic
lung
transplant
anoth
studi
tubulin
antibodi
present
signific
number
patient
bo
tubulin
circul
antibodi
may
induc
profibrot
growth
factor
airway
epitheli
cell
line
thu
provid
evid
autoimmunitylik
alloimmunitymay
induc
fibrosi
convers
also
shown
alloimmun
respons
lung
promot
develop
collagen
type
v
autoimmun
thu
pictur
becom
complex
alloimmun
autoimmun
innat
immun
system
discuss
later
may
trigger
allograft
airway
fibrosi
process
moreov
like
intertwin
discuss
previous
associ
acut
reject
bo
report
earli
late
reject
episod
yet
mani
patient
acut
reject
develop
bo
patient
bo
never
experienc
acut
reject
one
possibl
explan
use
intens
induct
mainten
immunosuppress
aggress
treatment
reject
might
uncoupl
associ
acut
reject
bo
anoth
potenti
explan
howev
bosbo
might
trigger
nonalloimmunedepend
factor
may
directli
injur
airwaysa
case
gastric
aspirationandor
augment
alloimmun
respons
via
activ
innat
immun
system
case
respiratori
bacteri
viral
infect
bacteri
colon
graft
formerli
believ
consequ
bosbo
recent
report
howev
bacteri
colon
notabl
pseudomona
aeruginosa
might
one
possibl
alloimmuneindepend
risk
factor
bosob
studi
botha
colleagu
includ
lung
transplant
recipi
develop
allograft
colon
pseudomona
strongli
associ
develop
bo
within
year
transplant
colon
colon
respect
isol
pseudomona
predat
diagnosi
bo
affect
patient
median
exceed
day
similar
find
report
aspergillu
colon
valentin
colleagu
analyz
role
bacteri
fungal
respiratori
tract
infect
develop
bo
singlecent
studi
compris
lung
recipi
surviv
least
day
multivari
analysi
indic
gramneg
gramposit
fungal
pneumonia
associ
develop
bo
gramposit
pneumonia
fungal
pneumonia
first
day
confer
hazard
ratio
respect
conclud
earli
recognit
treatment
pathogen
might
improv
longterm
outcom
kumar
colleagu
screen
serial
surveil
diagnost
bal
specimen
obtain
lung
transplant
recipi
year
communityacquir
respiratori
viral
infect
carvi
use
sensit
molecular
method
simultan
detect
respiratori
viral
typessubtyp
respiratori
virusesrhinoviru
parainfluenza
viru
coronaviru
influenza
metapneumoviru
respiratori
syncyti
viruswer
isol
patient
least
one
bal
sampl
biopsyproven
acut
reject
declin
fev
greater
equal
occur
carviposit
patient
within
month
carvi
compar
carvineg
patient
signific
differ
seen
incid
acut
reject
symptomat
asymptomat
patient
biopsyprov
bo
diagnos
patient
within
year
infect
indic
symptomat
asymptomat
viral
infect
may
trigger
acut
reject
andor
bosbo
contrast
gottlieb
colleagu
found
symptomat
carvi
increas
risk
bo
chlamydia
pneumonia
human
herpesviru
respiratori
infect
also
known
increas
risk
bo
cmv
mismatch
ie
seroneg
recipi
receiv
organ
seroposit
donor
cmv
pneumon
associ
bo
sever
seri
other
found
margin
relationship
differ
might
account
least
part
differ
strategi
use
match
recipi
regard
cmv
statu
prevent
treat
cmv
ill
decad
valentin
colleagu
report
cmv
pneumon
within
first
day
confer
hazard
ratio
develop
bo
group
report
experi
ganciclovir
gcv
prophylaxi
patient
surviv
least
day
cmv
pneumon
occur
patient
group
respect
nineti
patient
receiv
indefinit
gcv
prophylaxi
wherea
patient
discontinu
prophylaxi
stop
cumul
incid
cmv
pneumon
indefinit
gcv
prophylaxi
stop
group
year
respect
stop
cohort
patient
develop
cmv
pneumon
gcv
stop
develop
bo
risk
cmv
pneumon
stop
cohort
significantli
higher
gcv
prophylaxi
discontinu
within
first
year
bosfre
surviv
surviv
howev
similar
across
group
contrari
tamm
colleagu
show
seri
cmv
pneumon
treat
gcv
risk
factor
bo
affect
surviv
gastroesophag
reflux
diseas
gerd
thought
risk
factor
develop
progress
bosob
gerd
observ
approxim
half
lung
transplant
patient
preval
delay
gastric
empti
also
high
addit
patient
impair
cough
reflex
lung
denerv
alter
mucociliari
clearanc
taken
togeth
factor
increas
likelihood
aspir
subsequ
airway
injuri
pepsin
bile
acid
readili
found
bal
fluid
mani
lung
transplant
recipi
confirm
frequent
occurr
gastric
aspir
find
increas
bile
acid
bal
fluid
marker
nonacid
reflux
correl
presenc
bosbo
exposur
airway
epithelium
bile
acid
may
predispos
colon
pseudomona
aeruginosa
airway
neutrophilia
concern
gerd
increas
risk
bo
gener
trend
propos
surgic
solut
name
gastric
fundopl
recipi
present
signific
gerd
support
evid
strategi
deriv
retrospect
studi
gastric
fundopl
within
month
transplant
associ
greater
freedom
bo
increas
surviv
anoth
studi
center
show
fundopl
improv
lung
function
mani
patient
establish
bo
adopt
radic
approach
everi
singl
lung
transplant
recipi
howev
import
awar
best
way
diagnos
gerd
lung
transplant
recipientsph
monitor
versu
imped
monitoringi
present
controversi
gerda
well
cough
reflexmay
improv
time
fundopl
may
seriou
side
effect
eg
signific
weight
loss
import
recipi
signific
malnutrit
protect
function
surgic
sleev
may
wane
time
precis
indic
time
choic
fundopl
techniqu
yet
defin
overal
impact
lung
function
surviv
unknown
control
studi
date
allograft
ischemia
may
aris
period
warm
ischemia
explant
absenc
bronchial
arteri
reanastomosi
implant
small
airway
microvascular
damag
later
time
point
studi
lung
transplant
recipi
develop
primari
graft
dysfunct
sever
form
ischemiareperfus
lung
injuri
complic
independ
risk
factor
bo
allograft
ischemia
might
result
hypox
inflammatori
condit
lead
vascular
remodel
angiogenesi
may
turn
potent
stimulu
airway
fibrosi
gain
better
understand
complex
interact
airway
ischemia
vascular
remodel
angiogenesismedi
airway
fibroprolifer
might
becom
increasingli
possibl
ration
design
therapi
halt
condit
maladapt
fibrosi
possibl
decreas
risk
bosbo
role
risk
factor
bo
graft
ischem
time
donorrecipi
gender
size
mismatch
type
surgic
procedur
current
controversi
wide
accept
bosbo
involv
neutrophil
airway
inflamm
although
featur
lack
substanti
proport
patient
recent
studi
summar
verleden
colleagu
shown
interleukin
il
may
import
role
develop
bosbo
potent
indirect
neutrophilattract
chemokin
abil
induc
secret
differ
cell
type
airway
increas
airway
patient
bosbo
induc
product
airway
smooth
muscl
epitheli
cell
turn
promot
airway
neutrophilia
axi
may
trigger
alloimmun
autoimmun
mechan
airway
bacteri
colon
gerd
reason
bo
accompani
airway
neutrophilia
patient
other
remain
unclear
effect
azm
inflammatori
process
like
primarili
account
abil
inhibit
pathway
potenti
mechan
includ
posit
effect
azm
gerd
azm
known
agonist
motilin
well
inhibitori
effect
bacteri
growth
import
stress
bo
newli
describ
phenotyp
chronic
allograft
dysfunct
syndrom
defin
clinic
criteria
chang
pulmonari
function
radiograph
featur
analysi
bal
cellular
alon
combin
entiti
mere
descript
sort
specif
pathogen
pathway
risk
factor
patholog
prognosi
patient
may
one
phenotyp
time
time
differ
pathogen
pathway
patholog
may
coexist
discuss
previous
work
requir
understand
clinic
relev
pathogenesi
entiti
well
mechan
differ
risk
factor
produc
one
phenotyp
anoth
time
still
work
current
definit
bo
ie
progress
irrevers
airflow
obstruct
due
loss
small
airway
function
attribut
bo
although
difficulti
associ
stage
system
base
retrospect
diagnosi
exclusionari
criteria
acknowledg
bo
probabl
longer
presum
reflect
specif
process
chronic
reject
nonalloimmun
insult
like
often
contribut
develop
small
airway
lesion
final
whether
nrad
consid
subtyp
bo
distinct
entiti
current
debat
transplant
commun
discuss
later
extent
current
therapi
work
stop
slow
progress
bo
mostli
antiinflammatori
antifibrot
effect
therefor
like
effect
earli
stage
diseas
reason
variou
paramet
evalu
earli
biomark
bo
spirometri
appeal
earli
marker
wide
avail
noninvas
reproduc
rel
inexpens
two
studi
assess
predict
valu
bo
stage
diagnosi
bo
stage
studi
hachem
colleagu
includ
adult
bilater
lung
transplant
blt
recipi
fev
criterion
sensit
specif
posit
predict
valu
neg
predict
valu
respect
correspond
valu
modifi
fef
criterion
comput
use
baselin
valu
obtain
time
two
highest
fev
measur
respect
slt
recipi
studi
lama
colleagu
fev
criterion
also
predict
bo
predict
valu
superior
fef
criterion
superior
patient
underli
restrict
oppos
obstruct
physiolog
slope
alveolar
plateau
singlebreath
washout
test
reflect
homogen
ventil
distribut
increas
ventil
becom
heterogen
singlebreath
test
perform
use
inspir
pure
oxygen
measur
concentr
nitrogen
expir
ga
mixtur
contain
inert
gase
exampl
helium
also
use
inspir
concentr
gase
measur
expir
two
prospect
studi
assess
use
singlebreath
test
earli
detect
bo
blt
recipi
studi
nitrogen
slope
becam
abnorm
day
criterion
bo
met
posit
predict
valu
test
neg
predict
valu
approxim
furthermor
studi
estenn
colleagu
van
muylem
colleagu
show
helium
slope
even
earlier
marker
nitrogen
slope
fig
two
recent
studi
recipi
slt
emphysema
fibrosi
suggest
perform
later
decubitu
singlebreath
test
may
also
provid
inform
ventil
distribut
graft
patient
popul
exhal
gase
exhal
nitric
oxid
eno
wellrecogn
biomark
airway
inflamm
stabl
lung
transplant
recipi
patient
bo
eno
reflect
express
bronchial
epitheli
induc
synthas
posit
correl
airway
neutrophilia
carbon
monoxid
co
produc
endogen
stress
protein
heme
oxygenas
increas
varieti
oxidantinflammatorymedi
injuri
bo
lesion
heme
oxygenas
stain
correl
myeloperoxidas
express
reflect
oxid
load
neutrophil
infiltr
bronchial
wall
heme
oxygenas
degrad
heme
product
iron
biliverdin
co
therefor
eno
exhal
co
eco
may
reflect
airway
neutrophilia
henc
use
surrog
marker
bo
four
studi
shown
eno
increas
patient
bo
compar
patient
without
bo
independ
type
surgic
procedur
potenti
contribut
serial
eno
measur
earli
detect
bo
howev
difficult
assess
studi
recent
studi
recipi
bilater
graft
follow
approxim
day
van
muylem
colleagu
found
eno
eco
transient
increas
bo
return
baselin
bo
progress
fig
sensit
exhal
gase
diagnosi
bo
increas
approxim
valu
eno
eco
combin
yet
averag
increas
exhal
gase
preced
diagnosi
bo
may
due
least
part
signific
proport
patient
earli
bo
increas
airway
neutrophilia
summari
eno
eco
fair
sensit
nitrogen
helium
slope
good
sensit
detect
bo
biomark
also
high
neg
predict
valu
specif
posit
predict
valu
much
lower
low
specif
reflect
markerslik
fev
may
affect
complic
bo
eg
acut
reject
lymphocyt
bronchiol
infect
clinic
point
view
high
neg
predict
valu
help
detect
condit
may
confound
diagnosi
bo
absenc
signific
rise
exhal
biomark
bo
unlik
explan
declin
spirometri
convers
persist
rise
slope
eno
eco
interpret
warn
signal
prompt
close
monitor
patient
lung
function
clinic
condit
sever
surrog
marker
bo
propos
clinic
util
limit
one
follow
factor
invas
potenti
toxic
expens
wide
avail
predict
valu
appropri
test
controversi
surrog
marker
includ
exhal
breath
condens
induc
sputum
analysi
cellular
composit
inflammatori
marker
bal
fluid
imag
techniqu
ctin
particular
quantif
air
trap
full
expir
see
fig
intervent
target
risk
factor
may
prevent
develop
bo
valuabl
therapi
often
ineffect
bo
establish
context
optim
immunosuppress
regimen
prevent
occurr
acut
reject
critic
issu
discuss
previous
sever
studi
look
effect
increas
net
level
immunosuppress
eg
use
highdos
methylprednisolon
cytolyt
therapi
methotrex
andor
chang
mainten
regimen
eg
shift
cyclosporin
tacrolimu
azathioprin
mycophenol
mofetil
ad
inhal
cyclosporin
patient
establish
bo
review
knoop
estenn
patient
modal
shown
stabil
lung
function
decreas
rate
declin
fev
short
period
time
small
number
patient
studi
mostli
retrospect
design
studi
lack
adequ
control
group
rel
short
followup
time
howev
make
difficult
assess
effect
treatment
singl
strategi
prove
success
anoth
addit
augment
immunosuppress
increas
risk
toxic
predispos
intercurr
bronchopulmonari
infect
must
factor
riskbenefit
analysi
may
promot
progress
bo
discuss
previous
discuss
previous
sever
studi
followup
week
shown
macrolid
treatment
improv
fev
approxim
onethird
patient
differ
bo
stage
two
studi
assess
longterm
effect
azm
studi
gottlieb
colleagu
includ
patient
median
followup
year
studi
vo
colleagu
includ
patient
treat
median
time
day
initi
respons
defin
increas
fev
observ
patient
subsequ
relaps
multivari
analysi
initi
respons
azm
earlier
posttranspl
time
initi
treatment
protect
factor
diseas
progress
relaps
contrast
level
bal
neutrophilia
predict
valu
longitudin
data
thu
show
azm
provid
sustain
function
improv
longterm
small
minor
patient
bo
approxim
observ
suggest
therefor
patient
even
nrad
phenotyp
bo
condit
worsen
time
despit
rel
modest
effect
azm
lung
function
studi
patient
bo
shown
treatment
associ
signific
reduct
risk
death
studi
gottlieb
colleagu
vo
colleagu
respond
significantli
better
overal
surviv
compar
nonrespond
expect
differ
group
pronounc
respond
sustain
respons
taken
account
use
azm
prevent
bo
ie
patient
still
bo
stage
may
even
greater
clinic
impact
use
treatment
recent
prospect
random
trial
azm
patient
versu
placebo
patient
vo
colleagu
initi
treatment
discharg
follow
patient
year
bo
occur
less
patient
receiv
azm
placebo
bosfre
surviv
better
azm
patient
receiv
azm
demonstr
better
fev
lower
bal
neutrophilia
less
system
inflamm
differ
surviv
group
may
due
short
followup
time
larg
retrospect
studi
publish
johnson
colleagu
found
patient
receiv
statin
first
year
transplant
treatment
hypercholesterolemia
less
risk
develop
bo
patient
treat
addit
patient
receiv
statin
less
like
develop
sever
bo
better
surviv
unfortun
subsequ
report
confirm
observ
control
studi
vitro
demonstr
simvastatin
attenu
releas
airway
neutrophil
remodel
mediat
primari
bronchial
epitheli
cell
stabl
lung
transplant
patient
inhibit
upregul
transform
growth
factor
b
practic
mani
lung
transplant
program
systemat
prescrib
statin
order
exploit
immunomodulatori
effect
even
true
clinic
benefit
still
hypothet
fisher
colleagu
summar
experi
total
lymphoid
irradi
patient
treat
progress
bo
recipi
complet
treatment
rate
declin
fev
decreas
mlmo
pretot
lymphoid
irradi
mlmo
posttot
lymphoid
irradi
patient
greater
rate
function
declin
treatment
like
respond
result
studi
promis
absenc
adequ
power
random
control
trial
regard
provid
suggest
rather
convinc
evid
two
recent
singlecent
report
document
experi
extracorpor
photopheresi
treatment
bo
benden
colleagu
report
seri
patient
variou
stage
bo
rate
declin
fev
mlmo
photopheresi
mlmo
complet
cycl
complic
relat
therapi
record
studi
larger
studi
patient
bo
morrel
colleagu
document
similarli
dramat
reduct
rate
declin
fev
mlmo
prior
treatment
mlmo
month
initi
photopheresi
eight
patient
experienc
catheterrel
bacteremia
one
patient
catheterassoci
thrombu
one
patient
experienc
transient
hypotens
treatment
mechan
photopheresi
exert
immunomodulatori
antiinflammatori
effect
remain
poorli
understood
absenc
random
trial
prematur
endors
photopheresi
definit
therapi
bo
novick
colleagu
report
result
retranspl
perform
center
worldwid
perform
bo
report
indic
earli
surviv
retransplant
reduc
compar
first
transplant
result
retranspl
perform
bo
differ
done
indic
addit
recurr
bo
observ
frequenc
similar
seen
first
transplant
subsequ
three
singlecent
report
confirm
observ
colleagu
report
longterm
outcom
singlelung
retransplant
bo
median
time
primari
lung
transplant
retransplant
month
rang
month
actuari
surviv
rate
year
year
year
retransplant
respect
ten
patient
die
longterm
followup
infect
retain
graft
initi
site
fatal
infect
patient
two
patient
experienc
disabl
chronic
purul
expector
aris
old
graft
lung
retransplant
thu
offer
viabl
therapeut
option
select
slt
recipi
bo
given
morbid
mortal
relat
retain
graft
team
favor
replac
primari
graft
retransplant
consid
strueber
colleagu
report
redotranspl
among
lung
transplant
procedur
perform
institut
retransplant
bo
achiev
surviv
rate
respect
differ
observ
firsttim
lung
transplant
recipi
similar
incid
bo
retransplant
bo
versu
first
procedur
group
publish
similar
result
retransplant
perform
children
present
lung
transplant
perform
yearli
worldwid
retransplant
assess
procedur
medic
issu
issu
equit
use
scarc
resourc
need
address
chronic
allograft
dysfunct
especi
bosbo
remain
major
obstacl
longterm
surviv
lung
transplant
major
advanc
understand
risk
factor
pathogen
mechan
lead
irrevers
small
airway
lesion
made
new
option
prevent
treatment
bosbo
avail
doubt
come
year
improv
abil
cope
devast
complic
lung
transplant
